Compound C Protects Mice from HFD-Induced Obesity and Nonalcoholic Fatty Liver Disease
Objectives. The aim of this study was to investigate the effects of compound C on an in vivo mouse model of high-fat diet- (HFD-) induced obesity and hepatosteatosis. Methods. C57BL/6 mice were fed with a standard diet (n = 5) for 16 weeks and then injected saline once a day for 4 weeks as the norma...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2019-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2019/3206587 |
id |
doaj-0411cf0778b142198949bfd5e60d6a06 |
---|---|
record_format |
Article |
spelling |
doaj-0411cf0778b142198949bfd5e60d6a062020-11-25T00:40:03ZengHindawi LimitedInternational Journal of Endocrinology1687-83371687-83452019-01-01201910.1155/2019/32065873206587Compound C Protects Mice from HFD-Induced Obesity and Nonalcoholic Fatty Liver DiseaseFang Wang0Yuxing Liu1Jingjing Yuan2Wenjun Yang3Zhaohui Mo4The Endocrinology Department of the Third Xiangya Hospital, Central South University, Changsha, Hunan Province, ChinaThe Life Science School of Medicine, Central South University, Changsha, Hunan Province, ChinaThe Endocrinology Department of the Third Xiangya Hospital, Central South University, Changsha, Hunan Province, ChinaThe Endocrinology Department of the Third Xiangya Hospital, Central South University, Changsha, Hunan Province, ChinaThe Endocrinology Department of the Third Xiangya Hospital, Central South University, Changsha, Hunan Province, ChinaObjectives. The aim of this study was to investigate the effects of compound C on an in vivo mouse model of high-fat diet- (HFD-) induced obesity and hepatosteatosis. Methods. C57BL/6 mice were fed with a standard diet (n = 5) for 16 weeks and then injected saline once a day for 4 weeks as the normal chow group. Mice (n = 10) were fed with HFD for 16 weeks to induce obesity and hepatosteatosis and then divided into two groups: HFD + vehicle group injected with the vehicle solution (saline) and HFD + compound C group injected with compound C in saline (5 mg/kg i.p., once a day) for 4 weeks. Liver histology was observed. The expression levels of genes related to lipid metabolism and proinflammation in liver tissue were examined. NLRP3 inflammasome expression in liver tissue was detected by the western blot assay. HepG2 cells were pretreated with compound C and/or AICAR for 1 h and then treated with palmitic acid (PA) for 3 h. The cells were collected, and mRNA levels were determined. Results. There was a significant reduction in body-weight gain and daily food intake in the HFD + compound C group compared with the HFD + vehicle group (p<0.05). The glucose tolerance test (GTT) and insulin tolerance test (ITT) showed that compound C alleviated insulin resistance. Histology analysis showed a significant reduction of hepatic steatosis by compound C. Compound C also significantly decreased fatty acid synthesis genes, while increased fatty acid oxidation genes. Furthermore, compound C significantly reduced the expression of proinflammatory markers and NLRP3 inflammasome (p<0.05). Compound C enhanced mRNA levels of SOD1, SOD2, catalase, GPx1, and GPx4 and reduced the p-AMPK/AMPK ratio, which were stimulated by palmitic acid (PA). The effect was enhanced by AICAR. Conclusion. Our data suggest that compound C is a potent NAFLD suppressor and an attractive therapeutic target for hepatic steatosis and related metabolic disorders.http://dx.doi.org/10.1155/2019/3206587 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Fang Wang Yuxing Liu Jingjing Yuan Wenjun Yang Zhaohui Mo |
spellingShingle |
Fang Wang Yuxing Liu Jingjing Yuan Wenjun Yang Zhaohui Mo Compound C Protects Mice from HFD-Induced Obesity and Nonalcoholic Fatty Liver Disease International Journal of Endocrinology |
author_facet |
Fang Wang Yuxing Liu Jingjing Yuan Wenjun Yang Zhaohui Mo |
author_sort |
Fang Wang |
title |
Compound C Protects Mice from HFD-Induced Obesity and Nonalcoholic Fatty Liver Disease |
title_short |
Compound C Protects Mice from HFD-Induced Obesity and Nonalcoholic Fatty Liver Disease |
title_full |
Compound C Protects Mice from HFD-Induced Obesity and Nonalcoholic Fatty Liver Disease |
title_fullStr |
Compound C Protects Mice from HFD-Induced Obesity and Nonalcoholic Fatty Liver Disease |
title_full_unstemmed |
Compound C Protects Mice from HFD-Induced Obesity and Nonalcoholic Fatty Liver Disease |
title_sort |
compound c protects mice from hfd-induced obesity and nonalcoholic fatty liver disease |
publisher |
Hindawi Limited |
series |
International Journal of Endocrinology |
issn |
1687-8337 1687-8345 |
publishDate |
2019-01-01 |
description |
Objectives. The aim of this study was to investigate the effects of compound C on an in vivo mouse model of high-fat diet- (HFD-) induced obesity and hepatosteatosis. Methods. C57BL/6 mice were fed with a standard diet (n = 5) for 16 weeks and then injected saline once a day for 4 weeks as the normal chow group. Mice (n = 10) were fed with HFD for 16 weeks to induce obesity and hepatosteatosis and then divided into two groups: HFD + vehicle group injected with the vehicle solution (saline) and HFD + compound C group injected with compound C in saline (5 mg/kg i.p., once a day) for 4 weeks. Liver histology was observed. The expression levels of genes related to lipid metabolism and proinflammation in liver tissue were examined. NLRP3 inflammasome expression in liver tissue was detected by the western blot assay. HepG2 cells were pretreated with compound C and/or AICAR for 1 h and then treated with palmitic acid (PA) for 3 h. The cells were collected, and mRNA levels were determined. Results. There was a significant reduction in body-weight gain and daily food intake in the HFD + compound C group compared with the HFD + vehicle group (p<0.05). The glucose tolerance test (GTT) and insulin tolerance test (ITT) showed that compound C alleviated insulin resistance. Histology analysis showed a significant reduction of hepatic steatosis by compound C. Compound C also significantly decreased fatty acid synthesis genes, while increased fatty acid oxidation genes. Furthermore, compound C significantly reduced the expression of proinflammatory markers and NLRP3 inflammasome (p<0.05). Compound C enhanced mRNA levels of SOD1, SOD2, catalase, GPx1, and GPx4 and reduced the p-AMPK/AMPK ratio, which were stimulated by palmitic acid (PA). The effect was enhanced by AICAR. Conclusion. Our data suggest that compound C is a potent NAFLD suppressor and an attractive therapeutic target for hepatic steatosis and related metabolic disorders. |
url |
http://dx.doi.org/10.1155/2019/3206587 |
work_keys_str_mv |
AT fangwang compoundcprotectsmicefromhfdinducedobesityandnonalcoholicfattyliverdisease AT yuxingliu compoundcprotectsmicefromhfdinducedobesityandnonalcoholicfattyliverdisease AT jingjingyuan compoundcprotectsmicefromhfdinducedobesityandnonalcoholicfattyliverdisease AT wenjunyang compoundcprotectsmicefromhfdinducedobesityandnonalcoholicfattyliverdisease AT zhaohuimo compoundcprotectsmicefromhfdinducedobesityandnonalcoholicfattyliverdisease |
_version_ |
1725291659223105536 |